Gilead Sciences Announces 11 Percent Increase in First Quarter 2019 Dividend
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Gilead Sciences (GILD) PT Lowered to $90 at Raymond James
February 5, 2019 9:00 AM ESTRaymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $92.00) while maintaining a Strong Buy rating.
... MoreGilead Sciences (GILD) PT Lowered to $100 at Citi
February 5, 2019 6:59 AM ESTCiti analyst Robyn Karnauskas lowered the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $106.00) while maintaining a Buy rating. 2019 guidance anticipates double-digit y/y HIV growth and HCV stabilization. The company guided for generic impact in HCV, Letairis and Ranexa of ~$2.2B with... More
Gilead Sciences (GILD) PT Raised to $89 at RBC Capital
February 5, 2019 6:46 AM ESTRBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $86.00) while maintaining a Outperform rating following fourth quarter results.
Abrahams commented, "Parsing out the one-time effects that inflated HIV but depressed earnings this quarter,... More
Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance
February 4, 2019 4:02 PM ESTGilead Sciences (NASDAQ: GILD) reported Q4 EPS of $1.44, $0.27 worse than the analyst estimate of $1.71. Revenue for the quarter came in at $5.8 billion versus the consensus estimate of $5.49 billion.
GUIDANCE:
Gilead Sciences sees FY2019 revenue of $21.3-21.8 billion, versus the consensus... More
